Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
EPCORE DLBCL-3
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- NCT05660967 ↗
- Terminated
- Genmab
- Standard
We haven't built an HCP commentary report on EPCORE DLBCL-3 (epcoritamab and lenalidomide in Diffuse Large B-Cell Lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on EPCORE DLBCL-3 so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized, Multicenter, Global Phase 2 Trial
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Epcoritamab; Lenalidomide
- Arms
- Epcoritamab monotherapy · Experimental
- Epcoritamab in combination with lenalidomide · Experimental
- Enrollment
- 111
- Primary outcomes
- Complete Response (CR) rate
- Sponsor
- Genmab with AbbVie
- Start
- Mar 6, 2023
- Primary completion
- Jun 10, 2026
- Results posted
- No
- Registry record
- NCT05660967 · updated Oct 23, 2026
Publications
linked from the registry- Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, Lopez-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial. Lancet Haematol. 2026 Jul;13(7):e435-e448. doi: 10.1016/S2352-3026(26)00112-2. Epub 2026 Jun 12. PubMed 42285113